Acute asthma associated with sustained-release verapamil

被引:3
|
作者
BenNoun, L [1 ]
机构
[1] BEN GURION UNIV NEGEV,FAC HLTH SCI,DEPT FAMILY MED,IL-84105 BEER SHEVA,ISRAEL
关键词
asthma; verapamil; sustained-release;
D O I
10.1177/106002809703100514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil. CASE SUMMARY: A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil hydrocloride 40 mg rid to sustained-release verapamil 240 mg/d po for better hypertension control. After taking the first tablet, she developed dyspnea, cough, and wheezing. Antiasthmatic medications were prescribed, but the asthma symptoms did not improve. She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared. On rechallenge she developed severe dyspnea, cough, and wheezing 20 minutes after administration. The asthma resolved within 24 hours following three albuterol inhalations. The next day similar symptoms developed with rechallenge of the same brand of sustained-release verapamil in a 120-mg formulation, and verapamil was discontinued. Six months later she was again prescribed sustained-release verapamil 240 mg in another clinic where the physician was unaware of her previous reaction. Once again, severe dyspnea, cough, and wheezing developed. DISCUSSION: On four separate occasions the patient was challenged, advertently or inadvertently, with sustained-release verapamil. Similar symptoms developed after each challenge and resolved after discontinuing this preparation. Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration. CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
引用
收藏
页码:593 / 595
页数:3
相关论文
共 50 条
  • [21] THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE VERAPAMIL IN ANGINA OF EFFORT
    WEINER, DA
    KLEIN, MD
    CUTLER, SS
    CHEST, 1986, 89 (06) : S472 - S472
  • [22] PHARMACOKINETIC AND INVITRO CHARACTERISTICS OF SUSTAINED-RELEASE VERAPAMIL PRODUCTS
    DEVANE, JG
    KELLY, JG
    GEOGHEGAN, B
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (07) : 1233 - 1248
  • [23] SUSTAINED-RELEASE CHOLINE THEOPHYLLINATE IN NOCTURNAL ASTHMA
    RHIND, GB
    CONNAUGHTON, JJ
    MCFIE, J
    DOUGLAS, NJ
    FLENLEY, DC
    BRITISH MEDICAL JOURNAL, 1985, 291 (6509): : 1605 - 1607
  • [24] EFFECT OF SUSTAINED-RELEASE AMINOPHYLLINE IN CHRONIC ASTHMA
    ROCCHICCIOLI, KMS
    WHITE, JP
    MONIE, RDH
    THORAX, 1981, 36 (03) : 233 - 233
  • [25] THE EFFECT OF SUSTAINED-RELEASE THEOPHYLLINE IN NOCTURNAL ASTHMA
    FREEMAN, W
    PACKE, GE
    CAYTON, RM
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1991, 45 (01): : 21 - 25
  • [26] SUSTAINED-RELEASE THEOPHYLLINES IN CHILDREN WITH ASTHMA BRONCHIALE
    ZIMMERMANN, T
    ATEMWEGS-UND LUNGENKRANKHEITEN, 1988, 14 (10) : 480 - 484
  • [27] MASSIVE INGESTION OF SUSTAINED-RELEASE VERAPAMIL WITH A CONCRETION AND BOWEL INFARCTION
    SPORER, KA
    MANNING, JJ
    ANNALS OF EMERGENCY MEDICINE, 1993, 22 (03) : 603 - 605
  • [28] DILEVALOL IS COMPARABLE TO VERAPAMIL SUSTAINED-RELEASE IN THE TREATMENT OF HYPERTENSION IN THE ELDERLY
    WRIGHT, J
    DIETZ, A
    GRAY, J
    KAIHLANEN, P
    CIRANGLE, L
    CLINICAL RESEARCH, 1990, 38 (02): : A544 - A544
  • [29] Delayed Bowel Necrosis Following Overdose of Sustained-Release Verapamil
    French, L. K.
    Hendrickson, R. G.
    Horowitz, B. Z.
    CLINICAL TOXICOLOGY, 2012, 50 (04) : 362 - 362
  • [30] PHARMACOKINETIC MODEL OF VERAPAMIL (SUSTAINED-RELEASE) PROFILE IN TOXIC OVERDOSE
    GRAUMLICH, JF
    SPYKER, DA
    CANTILENA, LR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 156 - 156